Browse drugs

… severe ocular complications and vision loss if left untreated. Cyclosporine has gained recognition as an effective immunosuppressive therap…

… (95% CI) difference of −6.53 (−12.47 to −0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to…

… police violence are indicative of industry agenda-setting. The menthol ban was not a prominent topic of discussion in AA/B subreddits …

…ratitis were randomised 1:1 to receive either natamycin 5% plus voriconazole 1% (combination therapy) or natamycin 5% plus placebo (monotherapy…

… led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 week…

…Introduction Alemtuzumab is a potent disease-modifying therapy (DMT) for relapsing-remit…

…or secondary efficacy endpoints favoured rimegepant vs placebo. Rimegepant was well tolerated.Conclusions Rimegepant 75 mg EOD demonstrate…

…lammatory neuropathies. Work is underway to measure peripherin, periaxin, and NfL in larger, deeply phenotyped patient cohorts. We will …

…seen in subgroup analyses of specific triptans (rizatriptan and sumatriptan) and in chronic migraine patients.Conclusions Patients from the…

…NfL was higher in all neuropathy groups versus HC (all p<0.01). Periaxin was elevated in two out of eight CMT2A patients, two out of eig…

… and that, in our patient with Gly53Ala ATTRv amyloidosis, 61mg tafamidis therapy may not prevent CNS progression. He is planned to be co…

…4 patients, insulin and daily monitoring should have continued. Steroids were stopped for 18/30 patients; 11/12 continuing steroids had …